<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67190">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01983839</url>
  </required_header>
  <id_info>
    <org_study_id>MOXI-274-13</org_study_id>
    <secondary_id>2007-58-0010</secondary_id>
    <nct_id>NCT01983839</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Moxifloxacin in Patients With Pneumonia</brief_title>
  <official_title>Pharmacokinetics of Moxifloxacin in Patients With Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At the Department of Infectious Diseases, Aarhus Denmark, Moxifloxacin is used in the
      treatment of severe pneumonia. Due to the risk of cardiac toxicity, it is not recommended to
      give more than one dose of 400 mg daily. To investigate if this dose is enough to eradicate
      the bacteria, the investigators take a blood test from the patients treated with
      Moxifloxacin to determine the concentration og Moxifloxacin in the blood.

      Our hypothesis is, that 400 mg of Moxifloxacin is not enough in the treatment of severe
      pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the Department of Infectious Diseases, Aarhus Denmark, Moxifloxacin is used in the
      treatment of severe pneumonia. Due to the risk of cardiac toxicity, it is not recommended to
      give more than one dose of 400 mg daily. To investigate if this dose is enough to eradicate
      the bacteria, we take a total of 4 blood tests from the patients treated with Moxifloxacin,
      to determine the concentration og Moxifloxacin in the blood and calculate the
      pharmacokinetics.

      We compare the  blood concentration with the minimal inhibitory concentration (MIC)for the
      bacteria found in the sputum or blood, or with known MIC-values for the most common
      bacterias causing pneumonia in Denmark.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>The concentration of Moxifloxacin in blood-plasma</measure>
    <time_frame>The first 3 days of Moxifloxacin treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Pharmacokinetics Moxifloxacin</arm_group_label>
    <description>Patients with pneumonia treated with Moxifloxacin</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pneumonia, admitted to the Department of Infectious diseases, Aarhus
        University Hospital, Denmark
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pneumonia,

          -  Treated with Moxifloxacin

        Exclusion Criteria:

          -  Under 18 years of age
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eskild Petersen, MD, Assoc. Prof., D.Sc.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Infectious Diseases, Aarhus University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristina Öbrink-Hansen, MD</last_name>
    <phone>+45 7845 2845</phone>
    <email>krisoebr@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eskild Petersen, MD, Assoc. Prof., D.Sc.</last_name>
    <phone>7845 2817</phone>
    <email>joepeter@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Infectious Diseases, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus N</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Öbrink-Hansen, MD</last_name>
      <phone>+45 7845 2845</phone>
      <email>krisoebr@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Eskild Petersen, MD, Assoc. Prof., D.Sc.</last_name>
      <phone>+45 7845 2817</phone>
      <email>joepeter@rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 13, 2013</lastchanged_date>
  <firstreceived_date>July 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Kristina Öbrink-Hansen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Moxifloxacin</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
